Exact Sciences stock holds near $104.94 as analysts trim
Published on 08/17/2026 at 13:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences Corporation stock (ISIN US30063P1057) closed at $104.94 on August 17, 2026, up $1.02, or 0.98%, after a session that ranged from $104.90 to $104.98. The latest quarterly table shows revenue of $850 million for December 2025, up from $811 million in September 2025, while analysts tracked on MarketBeat now put the average 12-month target at $98.21.
Revenue still climbs
That December 2025 revenue figure also marked a step up from $706 million in March 2025 and $706.78 million in the quarter-trailing snapshot used by the market portal, showing that the business entered 2026 with a firmer top line. Gross profit reached $583 million in December 2025, compared with $562 million in September 2025, which kept the quarterly trend moving in the right direction.
For investors, the gap between the $104.94 close and the $98.21 average target now stands out more than the day change itself. The consensus view also leaves room for caution, because the same analyst set shows a high target of $105.00 and a low of $75.00, a spread that still points to a divided read on the shares.
What the trend says
Historically, the company posted full-year revenue of $2.758 billion in December 2025, up from $2.499 billion in December 2024, which helps explain why the stock still attracts attention even after a strong run. The quarterly revenue climb from $706 million in March 2025 to $850 million in December 2025 is the cleanest current comparison in the available data.
That trend matters more than a single session. It gives the stock a support layer from operating momentum while leaving valuation sensitive to any slowdown in the next reported quarter.
Diagnostics still matter
Exact Sciences remains tied to its cancer diagnostics franchise, led by Cologuard, which is the company’s best-known screening product. That product mix keeps recurring test demand and reimbursement trends central to the investment case.
Close and trading level
The stock finished at $104.94 on August 17, 2026, with a one-day gain of 0.98%. MarketBeat’s analyst snapshot puts the average target at $98.21, so the shares are trading above that level even after the latest close.
Fact box
Company: Exact Sciences Corporation
ISIN: US30063P1057
Ticker: EXAS
Exchange: Nasdaq
Price (as of August 17, 2026): $104.94 USD
Sector / Industry: Health Care / Diagnostics & Research
Index membership: Nasdaq-100
More on Exact Sciences stock
Cologuard remains the key product that investors watch alongside the company’s quarterly revenue trend and analyst valuation backdrop.
